| NCT03402191 |
L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension |
https://ClinicalTrials.gov/show/NCT03402191 |
Recruiting |
Tanta University |
2023-12-31 |
| NCT03381833 |
A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia |
https://ClinicalTrials.gov/show/NCT03381833 |
Recruiting |
La Jolla Pharmaceutical Company |
2019-10-31 |
| NCT04092205 |
Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation |
https://ClinicalTrials.gov/show/NCT04092205 |
Recruiting |
EmeraMed |
2020-03-30 |
| NCT03311243 |
Periodontal Therapy in Thalassemia Major Patients |
https://ClinicalTrials.gov/show/NCT03311243 |
Completed |
King Saud University |
2017-04-10 |
| NCT03275051 |
Long-term Follow-up of Subjects Treated With OTL-300 for Transfusion Dependent Beta-thalassemia Study (TIGET-BTHAL) |
https://ClinicalTrials.gov/show/NCT03275051 |
Enrolling by invitation |
Orchard Therapeutics |
2025-12-01 |
| NCT03271541 |
A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia |
https://ClinicalTrials.gov/show/NCT03271541 |
Completed |
Hoffmann-La Roche |
2018-06-29 |
| NCT03207009 |
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia |
https://ClinicalTrials.gov/show/NCT03207009 |
Recruiting |
bluebird bio |
2022-06-30 |
| NCT03171831 |
Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major |
https://ClinicalTrials.gov/show/NCT03171831 |
Recruiting |
First Affiliated Hospital of Guangxi Medical University |
2021-12-31 |
| NCT03117192 |
Zinc Supplementation on Cellular Immunity in Thalassemia Major |
https://ClinicalTrials.gov/show/NCT03117192 |
Completed |
Fakultas Kedokteran Universitas Indonesia |
2014-02-01 |
| NCT03101423 |
Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism |
https://ClinicalTrials.gov/show/NCT03101423 |
Active, not recruiting |
First Affiliated Hospital of Guangxi Medical University |
2019-12-31 |
| NCT03095326 |
Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia |
https://ClinicalTrials.gov/show/NCT03095326 |
Completed |
Fakultas Kedokteran Universitas Indonesia |
2014-02-01 |
| NCT02986698 |
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) |
https://ClinicalTrials.gov/show/NCT02986698 |
Recruiting |
University of California, San Francisco |
2022-02-28 |
| NCT02984475 |
The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major |
https://ClinicalTrials.gov/show/NCT02984475 |
Recruiting |
Cairo University |
2018-12-31 |
| NCT02950857 |
A Study of EPEG in Beta Thalassemia Patients |
https://ClinicalTrials.gov/show/NCT02950857 |
Completed |
Prolong Pharmaceuticals |
2017-09-27 |
| NCT02906202 |
A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype |
https://ClinicalTrials.gov/show/NCT02906202 |
Active, not recruiting |
bluebird bio |
2022-02-28 |
| NCT02744560 |
Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C |
https://ClinicalTrials.gov/show/NCT02744560 |
Completed |
Tanta University |
2017-12-31 |
| NCT02744547 |
Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C |
https://ClinicalTrials.gov/show/NCT02744547 |
Completed |
Tanta University |
2017-12-31 |
| NCT02744105 |
Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C |
https://ClinicalTrials.gov/show/NCT02744105 |
Completed |
Tanta University |
2017-12-31 |
| NCT02674607 |
the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children |
https://ClinicalTrials.gov/show/NCT02674607 |
Completed |
Tanta University |
2017-10-31 |
| NCT02671695 |
Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia |
https://ClinicalTrials.gov/show/NCT02671695 |
Completed |
Tanta University |
2018-04-30 |
| NCT02604433 |
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia |
https://ClinicalTrials.gov/show/NCT02604433 |
Active, not recruiting |
Celgene |
2017-11-24 |
| NCT02597595 |
Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major |
https://ClinicalTrials.gov/show/NCT02597595 |
Completed |
Tanta University |
2017-10-31 |
| NCT02559648 |
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis |
https://ClinicalTrials.gov/show/NCT02559648 |
Completed |
Laikο General Hospital, Athens |
2016-12-31 |
| NCT02453477 |
Gene Therapy for Transfusion Dependent Beta-thalassemia |
https://ClinicalTrials.gov/show/NCT02453477 |
Active, not recruiting |
IRCCS San Raffaele |
2019-08-31 |
| NCT02435901 |
HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity |
https://ClinicalTrials.gov/show/NCT02435901 |
Active, not recruiting |
Northwell Health |
2019-01-31 |
| NCT02326597 |
Decision Aid for Therapeutic Options In Sickle Cell Disease |
https://ClinicalTrials.gov/show/NCT02326597 |
Completed |
Emory University |
2017-04-17 |
| NCT02268409 |
ACE-536 Extension Study - Beta Thalassemia |
https://ClinicalTrials.gov/show/NCT02268409 |
Active, not recruiting |
Acceleron Pharma, Inc. |
2020-02-29 |
| NCT02198508 |
Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients |
https://ClinicalTrials.gov/show/NCT02198508 |
Completed |
China Medical University Hospital |
2008-07-31 |
| NCT02179359 |
Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies |
https://ClinicalTrials.gov/show/NCT02179359 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2020-08-31 |
| NCT02151526 |
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease |
https://ClinicalTrials.gov/show/NCT02151526 |
Completed |
bluebird bio |
2019-02-26 |
| NCT02105766 |
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure |
https://ClinicalTrials.gov/show/NCT02105766 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2021-08-31 |
| NCT01284738 |
Beta-thalassemia and Microparticles |
https://ClinicalTrials.gov/show/NCT01284738 |
Completed |
Assistance Publique Hopitaux De Marseille |
2014-02-28 |
| NCT02049450 |
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. |
https://ClinicalTrials.gov/show/NCT02049450 |
Completed |
Novartis |
2016-04-12 |
| NCT04364269 |
Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia |
https://ClinicalTrials.gov/show/NCT04364269 |
Recruiting |
Vifor (International) Inc. |
2021-05-31 |
| NCT01966367 |
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01966367 |
Active, not recruiting |
Columbia University |
2022-01-31 |
| NCT01917708 |
Bone Marrow Transplant With Abatacept for Non-Malignant Diseases |
https://ClinicalTrials.gov/show/NCT01917708 |
Completed |
Emory University |
2019-09-19 |
| NCT00006136 |
Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia |
https://ClinicalTrials.gov/show/NCT00006136 |
Completed |
Office of Rare Diseases (ORD) |
NA |
| NCT01752153 |
Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major |
https://ClinicalTrials.gov/show/NCT01752153 |
Completed |
Shiraz University of Medical Sciences |
2012-09-30 |
| NCT01749540 |
Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia |
https://ClinicalTrials.gov/show/NCT01749540 |
Completed |
Acceleron Pharma, Inc. |
2015-11-30 |
| NCT01745120 |
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants |
https://ClinicalTrials.gov/show/NCT01745120 |
Completed |
bluebird bio |
2018-02-08 |
| NCT01740531 |
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion |
https://ClinicalTrials.gov/show/NCT01740531 |
Completed |
Cerus Corporation |
2017-12-21 |
| NCT01709032 |
Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia |
https://ClinicalTrials.gov/show/NCT01709032 |
Completed |
Children’s Hospital of Philadelphia |
2015-08-01 |
| NCT01642758 |
Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon |
https://ClinicalTrials.gov/show/NCT01642758 |
Completed |
Boston University |
2012-11-30 |
| NCT01610297 |
Post Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01610297 |
Completed |
Novartis |
2015-10-31 |
| NCT01609595 |
Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand |
https://ClinicalTrials.gov/show/NCT01609595 |
Completed |
Boston University |
2012-11-30 |
| NCT01597765 |
Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients |
https://ClinicalTrials.gov/show/NCT01597765 |
Completed |
Mahidol University |
2011-06-30 |
| NCT01571635 |
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia. |
https://ClinicalTrials.gov/show/NCT01571635 |
Active, not recruiting |
Celgene |
2015-07-02 |
| NCT01395199 |
Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major |
https://ClinicalTrials.gov/show/NCT01395199 |
Completed |
University of Campinas, Brazil |
2015-02-28 |
| NCT04390971 |
Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia |
https://ClinicalTrials.gov/show/NCT04390971 |
Recruiting |
Institute of Hematology & Blood Diseases Hospital |
2021-10-31 |
| NCT04353986 |
PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders |
https://ClinicalTrials.gov/show/NCT04353986 |
Recruiting |
Ain Shams University |
2020-04-30 |
| NCT04292314 |
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia |
https://ClinicalTrials.gov/show/NCT04292314 |
Recruiting |
Beni-Suef University |
2020-10-31 |
| NCT04260516 |
The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major |
https://ClinicalTrials.gov/show/NCT04260516 |
Completed |
Beni-Suef University |
2019-12-03 |
| NCT04211480 |
Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells |
https://ClinicalTrials.gov/show/NCT04211480 |
Recruiting |
Shanghai Bioray Laboratory Inc. |
2021-05-30 |
| NCT04143724 |
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Subjects Who Require Regular RBC Transfusions Due to Beta (β)-Thalassemia. |
https://ClinicalTrials.gov/show/NCT04143724 |
Recruiting |
Celgene |
2021-12-04 |
| NCT04090268 |
Precision Exercise in Children With Malignant Hemopathies |
https://ClinicalTrials.gov/show/NCT04090268 |
Recruiting |
University of Milano Bicocca |
2021-04-03 |
| NCT04064060 |
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials |
https://ClinicalTrials.gov/show/NCT04064060 |
Recruiting |
Celgene |
2028-01-24 |
| NCT04054921 |
Safety Study for Beta Thalassemia Subjects on PTG-300 |
https://ClinicalTrials.gov/show/NCT04054921 |
Recruiting |
Protagonist Therapeutics, Inc. |
2021-05-10 |
| NCT04009525 |
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study |
https://ClinicalTrials.gov/show/NCT04009525 |
Recruiting |
First Affiliated Hospital of Guangxi Medical University |
2022-05-31 |
| NCT03993613 |
Apotransferrin in Patients With β-thalassemia |
https://ClinicalTrials.gov/show/NCT03993613 |
Recruiting |
Sanquin Plasma Products BV |
2020-05-01 |
| NCT03992001 |
Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients |
https://ClinicalTrials.gov/show/NCT03992001 |
Enrolling by invitation |
Università degli Studi di Ferrara |
2019-06-30 |
| NCT03961828 |
Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus |
https://ClinicalTrials.gov/show/NCT03961828 |
Completed |
Tanta University |
2018-12-31 |
| NCT03948737 |
The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell Membrane Beta-thalassemia Major |
https://ClinicalTrials.gov/show/NCT03948737 |
Completed |
Indonesia University |
2017-07-30 |
| NCT03877809 |
Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients |
https://ClinicalTrials.gov/show/NCT03877809 |
Recruiting |
Rare Partners srl Impresa Sociale |
2020-09-30 |
| NCT03802201 |
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia |
https://ClinicalTrials.gov/show/NCT03802201 |
Recruiting |
Protagonist Therapeutics, Inc. |
2020-08-31 |
| NCT03763656 |
Pharmacokinetics of Oral Hydroxyurea Solution |
https://ClinicalTrials.gov/show/NCT03763656 |
Recruiting |
Nova Laboratories Limited |
2021-01-31 |
| NCT03655678 |
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia |
https://ClinicalTrials.gov/show/NCT03655678 |
Recruiting |
Vertex Pharmaceuticals Incorporated |
2021-02-28 |
| NCT03653338 |
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias |
https://ClinicalTrials.gov/show/NCT03653338 |
Recruiting |
University of Pittsburgh |
2023-08-01 |
| NCT03637556 |
Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation |
https://ClinicalTrials.gov/show/NCT03637556 |
Recruiting |
DisperSol Technologies, LLC |
2020-07-31 |
| NCT03591575 |
Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children |
https://ClinicalTrials.gov/show/NCT03591575 |
Active, not recruiting |
Chiesi Canada Corp |
2020-11-01 |
| NCT03432364 |
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) |
https://ClinicalTrials.gov/show/NCT03432364 |
Active, not recruiting |
Sangamo Therapeutics |
2021-03-31 |
| NCT01224496 |
Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders |
https://ClinicalTrials.gov/show/NCT01224496 |
Completed |
Singapore General Hospital |
2011-08-31 |
| NCT01206075 |
Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major |
https://ClinicalTrials.gov/show/NCT01206075 |
Completed |
University of Washington |
2012-12-31 |
| NCT01186419 |
Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload |
https://ClinicalTrials.gov/show/NCT01186419 |
Completed |
Shire |
2012-12-31 |
| NCT01140321 |
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI |
https://ClinicalTrials.gov/show/NCT01140321 |
Completed |
Ente Ospedaliero Ospedali Galliera |
2010-05-31 |
| NCT01125254 |
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major |
https://ClinicalTrials.gov/show/NCT01125254 |
Completed |
University of Campinas, Brazil |
2011-07-31 |
| NCT01049854 |
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant |
https://ClinicalTrials.gov/show/NCT01049854 |
Completed |
New York Medical College |
2017-11-30 |
| NCT01039636 |
Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload |
https://ClinicalTrials.gov/show/NCT01039636 |
Completed |
FerroKin BioSciences, Inc. |
2010-12-31 |
| NCT00809042 |
Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia |
https://ClinicalTrials.gov/show/NCT00809042 |
Completed |
Shiraz University of Medical Sciences |
2007-11-30 |
| NCT03851055 |
Zinc Supplementation in Patients With β-Thalassemia Major Complicated With Diabetes Mellitus |
https://ClinicalTrials.gov/show/NCT03851055 |
Completed |
Ain Shams University |
2018-07-10 |
| NCT01639690 |
ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene |
https://ClinicalTrials.gov/show/NCT01639690 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-07-31 |
| NCT03889977 |
Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin |
https://ClinicalTrials.gov/show/NCT03889977 |
Completed |
University of Thessaly |
2019-08-30 |
| NCT00790127 |
Phase 1/2 Study of HQK-1001 in Patients With Beta Thalassemia |
https://ClinicalTrials.gov/show/NCT00790127 |
Completed |
HemaQuest Pharmaceuticals Inc. |
2010-05-31 |
| NCT00749515 |
Pilot Study for Patients With Poor Response to Deferasirox |
https://ClinicalTrials.gov/show/NCT00749515 |
Completed |
Boston Children’s Hospital |
2008-10-31 |
| NCT00800761 |
Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major |
https://ClinicalTrials.gov/show/NCT00800761 |
Completed |
Ospedale Microcitemico |
2006-06-30 |
| NCT00733811 |
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP |
https://ClinicalTrials.gov/show/NCT00733811 |
Completed |
Azienda Ospedaliera V. Cervello |
2008-01-31 |
| NCT00661726 |
Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia |
https://ClinicalTrials.gov/show/NCT00661726 |
Completed |
HealthCore-NERI |
2010-05-31 |
| NCT00658385 |
Assess the Feasibility and Safety of Granulocyte Colony Stimulating Factor (GCSF) Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major |
https://ClinicalTrials.gov/show/NCT00658385 |
Completed |
Memorial Sloan Kettering Cancer Center |
2011-02-28 |
| NCT00564941 |
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload |
https://ClinicalTrials.gov/show/NCT00564941 |
Completed |
Novartis |
2011-07-31 |
| NCT00560820 |
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload |
https://ClinicalTrials.gov/show/NCT00560820 |
Completed |
Novartis |
2012-04-30 |
| NCT00456690 |
Endocrine and Nutritional Assessment in B Thalassemia Major |
https://ClinicalTrials.gov/show/NCT00456690 |
Completed |
HaEmek Medical Center, Israel |
2014-12-31 |
| NCT00447694 |
Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment |
https://ClinicalTrials.gov/show/NCT00447694 |
Completed |
Novartis |
2009-11-30 |
| NCT00408447 |
Stem Cell Transplant in Sickle Cell Disease and Thalassemia |
https://ClinicalTrials.gov/show/NCT00408447 |
Active, not recruiting |
Columbia University |
2019-08-06 |
| NCT00390858 |
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. |
https://ClinicalTrials.gov/show/NCT00390858 |
Completed |
Novartis |
2008-02-29 |
| NCT00336362 |
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major |
https://ClinicalTrials.gov/show/NCT00336362 |
Completed |
University of Washington |
2010-08-31 |
| NCT00879242 |
Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec |
https://ClinicalTrials.gov/show/NCT00879242 |
Completed |
Novartis |
2011-05-31 |
| NCT00171301 |
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) |
https://ClinicalTrials.gov/show/NCT00171301 |
Completed |
Novartis |
2008-05-31 |
| NCT00171210 |
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload |
https://ClinicalTrials.gov/show/NCT00171210 |
Completed |
Novartis |
2008-04-30 |
| NCT00171171 |
A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis |
https://ClinicalTrials.gov/show/NCT00171171 |
Completed |
Novartis |
2006-11-30 |
| NCT00105495 |
Efficacy Study in Removing Excess Iron From the Heart |
https://ClinicalTrials.gov/show/NCT00105495 |
Completed |
ApoPharma |
NA |
| NCT00069862 |
Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia |
https://ClinicalTrials.gov/show/NCT00069862 |
Completed |
Sanofi |
NA |
| NCT00061763 |
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias |
https://ClinicalTrials.gov/show/NCT00061763 |
Completed |
Novartis |
2004-11-30 |
| NCT00061750 |
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions |
https://ClinicalTrials.gov/show/NCT00061750 |
Completed |
Novartis |
2004-11-30 |
| NCT00029380 |
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia |
https://ClinicalTrials.gov/show/NCT00029380 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
2006-08-31 |
| NCT00303329 |
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients |
https://ClinicalTrials.gov/show/NCT00303329 |
Completed |
Novartis |
2008-10-31 |
| NCT00005934 |
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia |
https://ClinicalTrials.gov/show/NCT00005934 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00005893 |
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders |
https://ClinicalTrials.gov/show/NCT00005893 |
Completed |
Office of Rare Diseases (ORD) |
NA |
| NCT00001958 |
Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia) |
https://ClinicalTrials.gov/show/NCT00001958 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00000595 |
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis |
https://ClinicalTrials.gov/show/NCT00000595 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
NA |
| NCT00000588 |
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone |
https://ClinicalTrials.gov/show/NCT00000588 |
Completed |
Case Western Reserve University |
NA |
| NCT00004378 |
Stem Cell Transplantation (SCT) for Genetic Diseases |
https://ClinicalTrials.gov/show/NCT00004378 |
Completed |
National Center for Research Resources (NCRR) |
NA |